Structure and Key Players of CDER's Public-Private Partnerships (PPPs)

The FDA's Center for Drug Evaluation and Research (CDER) operates public-private partnerships (PPPs) centered around the Critical Path Initiative, involving collaboration between government, academia, industry, and patient organizations. The Critical Path Institute (C-Path), serving as a key hub, is an independent non-profit organization established in 2005. It has built a global consortium network with over 1,600 scientists from 41 bio/pharma companies, regulatory agencies, and universities. Having secured a grant of up to $10.5 million over five years from the FDA, it functions as a de facto standard platform for regulatory science infrastructure.

GLDH Biomarker Qualification: A Game-Changer in Safety Assessment

On November 19, 2025, the FDA's Biomarker Qualification Program (BQP) officially qualified glutamate dehydrogenase (GLDH) as a safety biomarker for detecting drug-induced liver injury (DILI), based on the Predictive Safety Testing Consortium (PSTC) led by C-Path. This marks the first instance of clinical safety biomarker qualification in FDA history. It provides a tool to accurately distinguish liver toxicity from false positives caused by muscle damage, such as in patients with Duchenne Muscular Dystrophy, where conventional ALT/AST tests may be misleading. This achievement is the result of a joint study with the FNIH Biomarker Consortium and has the potential to transform the paradigm of safety monitoring in clinical trial design.

Expansion of Disease-Specific Consortia: AATD, Alzheimer's, and Diabetes

C-Path is actively expanding its disease-specific consortia. The Alpha-1 Antitrypsin Deficiency (AATD) Consortium (CPA-1), launched in 2023, is a joint partnership between the FDA's CDER and CBER. In April 2026, RNA editing company AIRNA joined as an industry partner, accelerating the development of new therapeutic modalities. In the field of Alzheimer's disease, the Critical Path for Alzheimer's Disease (CPAD) consortium (formerly CAMD) is developing disease progression modeling and clinical trial design optimization tools. In 2025, a public workshop on the development of new-onset type 1 diabetes was held, with over 400 stakeholders attending to discuss methodologies for evaluating beta-cell function preservation based on C-peptide.

Reagan-Udall Foundation and the Regulatory Science Ecosystem

The Reagan-Udall Foundation is an independent 501(c)(3) organization established by Congress to support the strengthening of the FDA's regulatory science capabilities. On December 9, 2025, C-Path was selected as an award recipient at the Innovations in Regulatory Science & Policy Awards, officially recognizing the achievements of the PPP model. This ecosystem is also connected to industry non-profits such as TransCelerate BioPharma, which promotes efficiency throughout the clinical research process.

Market Context and Future Prospects

The global biomarker market is projected to grow from $82.3 billion in 2023 to $318.8 billion in 2033, with an annual growth rate of 14.5%, and the new drug discovery market is expected to expand from $72 billion in 2025 to $1.741 billion in 2035 (CAGR of 9.24%). The FDA's Drug Development Tools (DDT) qualification program and ISTAND (Innovative Science and Technology Approaches for New Drugs) program serve as regulatory catalysts for this growth, and the next generation of evidence generation strategies will be unveiled at C-Path's 2026 Global Impact Conference.